Abstract
Background: Arterial stiffness is a pathological basis and risk factor for cardiovascular diseases, characterized by chronic inflammation. This study aimed to analyze the association between arterial stiffness, measured by the cardio-ankle vascular index (CAVI), and inflammatory indicators such as leukocyte subtype counts, platelet counts, and the monocyte-to-lymphocyte ratio (MLR). Methods: Data from 1,789 inpatients were divided into a training set (1,089) and a validation set (700). Simple and multiple linear regressions, along with logistic regression, were used to analyze the relationship between inflammatory markers and CAVI. Decision models were evaluated using ROC curves. Results: MLR was identified as a significant risk factor for arterial stiffness, particularly in men (OR 8.95). A cutpoint MLR of 0.19 showed 70% accuracy. Decision models achieved AUCs > 0.80. Conclusions: MLR is a potent predictor of arterial stiffness and could serve as a low-cost clinical indicator.
Introduction: The Inflammatory Roots of Arterial Stiffness
Arterial stiffness (AS) is a critical indicator of vascular aging and a major contributor to cardiovascular disease. Pathologically, it involves chronic inflammation that disrupts the balance of elastin within vessel walls. While tools like Pulse-Wave Velocity (PWV) are commonly used, they are often influenced by blood pressure fluctuations. The Cardio-Ankle Vascular Index (CAVI) provides a more stable, blood-pressure-independent measurement. However, CAVI requires specialized equipment not always available in primary care. This study explores whether routine, inexpensive blood markers—specifically white blood cell subtypes and their ratios—can serve as effective proxies for predicting AS.
Methods and Data Analysis
The researchers conducted a retrospective study using data from Wuhan Union Hospital, China. The cohort included a training set of 1,089 cases and a temporal validation set of 700 cases.
The study focused on several inflammatory indicators derived from complete blood counts:
- Neutrophils (NE), Monocytes (MO), Lymphocytes (LY), and Platelets (PLT).
- Ratios: Neutrophil-to-lymphocyte ratio (NLR), Monocyte-to-lymphocyte ratio (MLR), and Platelet-to-lymphocyte ratio (PLR).
Statistical methods included simple and multiple linear regressions to associate these markers with CAVI scores. Logistic regression was then used to build decision models to categorize patients into "Arterial Stiffness" (CAVI ≥ 9) or "Non-Arterial Stiffness" groups.
Key Insights: The Predictive Power of MLR
The study revealed that while individual cell counts correlate with stiffness, the Monocyte-to-Lymphocyte Ratio (MLR) is the most effective predictor. Biologically, monocytes act as pro-inflammatory agents that contribute to plaque formation, while lymphocytes often play a protective role. The MLR effectively captures the balance of this inflammatory "tug-of-war."
A notable finding was the gender dimorphism in predictive accuracy. The markers were significantly more potent in men. In the male subgroup, MLR accounted for an effect weight of 12.87% on the CAVI score, second only to age. After adjusting for covariates like BMI and hypertension, men with high MLR were nearly nine times more likely to exhibit arterial stiffness (OR 8.95).
Results and Clinical Implications
The developed decision models demonstrated high reliability, achieving an Area Under the Curve (AUC) of over 0.80 in both the training and validation datasets. A specific MLR threshold of 0.19 was identified, offering 70% accuracy for identifying arterial stiffness across the entire study population. These results remained consistent even after case-control matching to account for confounding factors like diabetes and age.
Discussion and Future Directions
While promising, the study's retrospective nature means it establishes correlation rather than causation. The observed gender differences likely stem from the anti-inflammatory effects of estrogen in women, a factor that requires further investigation through menopausal subgroup analysis. Future research should also integrate other biomarkers, such as C-reactive protein (CRP), to enhance model robustness. Ultimately, prospective multicenter trials are needed to validate these findings before MLR can be formally adopted as a standard screening tool for cardiovascular risk.
Summary updated